Advertisement
Screener

Capital International Investors Historic Quarter Change: Foreign ADRs, Added

Capital International Investors historic quarter change: Foreign ADRs, Added

In depositary receipts for foreign shares (depositary receipts and foreign shares traded over the counter), over 23 quarters from 2013-06-30 to 2026-06-30, Capital International Investors opened 0 positions, added to 16, reduced 8 and sold out of 4.

  • Q4 2025: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 3,060,616.
  • Q3 2025: Stock ASCENDIS PHARMA A/S; Country of operation —; Class SPONSORED ADR; Shares before 3,046,931.
  • Q3 2025: Stock TOTALENERGIES SE; Country of operation —; Class SPONSORED ADS; Shares before 3,395,870.
  • Q2 2025: Stock ASTRAZENECA PLC; Country of operation —; Class SPONSORED ADR; Shares before 31,285,560.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1562230), 23 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-12); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-13); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-11); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-13); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-13); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-12); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-13); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-13); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-13); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-14); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-15); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-12); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-08-14); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-03-02); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15); Q4 2013 (2013-09-30 to 2013-12-31, filed 2014-02-14); Q3 2013 (2013-06-30 to 2013-09-30, filed 2013-11-14). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2012-09-30. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q4 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR3,060,6163,063,943+3,327$608,481,067$653,355,205+$44,874,1382026-02-11
Q3 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR3,046,9313,060,616+13,685$525,900,291$608,481,067+$82,580,7762025-11-13
Q3 2025TOTALENERGIES SE
CUSIP 89151E109
SPONSORED ADS3,395,8703,423,484+27,614$208,845,912$211,296,892+$2,450,9802025-11-13
Q2 2025ASTRAZENECA PLC
CUSIP 046353108
SPONSORED ADR31,285,56031,404,983+119,423$2,300,849,034$2,194,439,575-$106,409,4592025-08-13
Q2 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR2,874,7923,046,931+172,139$448,065,081$525,900,291+$77,835,2102025-08-13
Q1 2025TOTALENERGIES SE
CUSIP 89151E109
SPONSORED ADS4,657,2775,013,491+356,214$253,728,423$321,615,582+$67,887,1592025-05-12
Q1 2025ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR2,863,2492,874,792+11,543$394,183,490$448,065,081+$53,881,5912025-05-12
Q4 2024ASTRAZENECA PLC
CUSIP 046353108
SPONSORED ADR36,821,15137,507,159+686,008$2,867,329,554$2,457,706,468-$409,623,0862025-02-13
Q4 2024ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR2,109,3902,863,249+753,859$314,953,021$394,183,490+$79,230,4692025-02-13
Q3 2024ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR2,104,2982,109,390+5,092$286,984,161$314,953,021+$27,968,8602024-11-13
Q3 2024ASTRAZENECA PLC
CUSIP 046353108
SPONSORED ADR36,703,71836,821,151+117,433$2,863,439,739$2,867,329,554+$3,889,8152024-11-13
Q3 2024TOTALENERGIES SE
CUSIP 89151E109
SPONSORED ADS4,902,0224,932,321+30,299$326,425,665$326,272,573-$153,0922024-11-13
Q2 2024ASTRAZENECA PLC
CUSIP 046353108
SPONSORED ADR34,521,87536,703,718+2,181,843$2,338,856,970$2,863,439,739+$524,582,7692024-08-13
Q2 2024TOTALENERGIES SE
CUSIP 89151E109
SPONSORED ADS4,858,0974,902,022+43,925$334,382,761$326,425,665-$7,957,0962024-08-13
Q1 2024ASCENDIS PHARMA A/S
CUSIP 04351P101
SPONSORED ADR2,181,2682,191,312+10,044$274,730,705$331,260,635+$56,529,9302024-05-14
Q1 2024TOTALENERGIES SE
CUSIP 89151E109
SPONSORED ADS4,758,0384,858,097+100,059$318,407,993$334,382,761+$15,974,7682024-05-14

Similar Firms

Firm NameCountry13F ValueHoldings
AMERIPRISE FINANCIAL INCUnited States$431.760B11,197
Legal & General Group PlcUnited Kingdom$432.387B8,115
BARCLAYS PLCUnited Kingdom$416.252B12,241
FRANKLIN TEMPLETON INCUnited States$408.305B14,782
VANGUARD FIDUCIARY TRUST COUnited States$391.624B3,983
LPL Financial LLCUnited States$376.560B5,964
ENVESTNET ASSET MANAGEMENT INCUnited States$373.578B4,703
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUnited States$480.980B19,242
DIMENSIONAL FUND ADVISORS LPUnited States$481.393B13,635
Nuveen, LLCUnited States$369.268B7,665